HRP20160538T1 - Postupci za ekspanziju stanice i uporaba tako proizvedenih stanica i obrađenog medija za terapiju - Google Patents
Postupci za ekspanziju stanice i uporaba tako proizvedenih stanica i obrađenog medija za terapiju Download PDFInfo
- Publication number
- HRP20160538T1 HRP20160538T1 HRP20160538TT HRP20160538T HRP20160538T1 HR P20160538 T1 HRP20160538 T1 HR P20160538T1 HR P20160538T T HRP20160538T T HR P20160538TT HR P20160538 T HRP20160538 T HR P20160538T HR P20160538 T1 HRP20160538 T1 HR P20160538T1
- Authority
- HR
- Croatia
- Prior art keywords
- cells
- adherent
- population
- adherent cells
- bioreactor
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 230000010261 cell growth Effects 0.000 title claims 2
- 238000002560 therapeutic procedure Methods 0.000 title claims 2
- 239000003636 conditioned culture medium Substances 0.000 title 1
- 230000001464 adherent effect Effects 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 210000005059 placental tissue Anatomy 0.000 claims 4
- 210000002536 stromal cell Anatomy 0.000 claims 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims 2
- 102100033620 Calponin-1 Human genes 0.000 claims 2
- 101710092112 Calponin-1 Proteins 0.000 claims 2
- 101100450032 Gallus gallus H2AZ2 gene Proteins 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 101001078082 Homo sapiens Reticulocalbin-3 Proteins 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 102100025343 Reticulocalbin-3 Human genes 0.000 claims 2
- 201000002491 encephalomyelitis Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 claims 1
- 102100022464 5'-nucleotidase Human genes 0.000 claims 1
- 102100036630 60S ribosomal protein L7a Human genes 0.000 claims 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 102300038161 CD44 antigen isoform 2 Human genes 0.000 claims 1
- 102000029816 Collagenase Human genes 0.000 claims 1
- 108060005980 Collagenase Proteins 0.000 claims 1
- 102100031334 Elongation factor 2 Human genes 0.000 claims 1
- 102100037241 Endoglin Human genes 0.000 claims 1
- 101710139370 Eukaryotic translation elongation factor 2 Proteins 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 101150067143 Hnrnph1 gene Proteins 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 1
- 101000853243 Homo sapiens 60S ribosomal protein L7a Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 1
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- QDFHPFSBQFLLSW-KQYNXXCUSA-N adenosine 2'-phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OP(O)(O)=O QDFHPFSBQFLLSW-KQYNXXCUSA-N 0.000 claims 1
- 210000001691 amnion Anatomy 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229960002424 collagenase Drugs 0.000 claims 1
- 210000005151 decidua basalis Anatomy 0.000 claims 1
- 210000005150 decidua parietalis Anatomy 0.000 claims 1
- 102000038379 digestive enzymes Human genes 0.000 claims 1
- 108091007734 digestive enzymes Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000008105 immune reaction Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0669—Bone marrow stromal cells; Whole bone marrow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Claims (9)
1. Postupak ekspanzije stanice, naznačen time da sadrži kultiviranje adherentnih stromalnih stanica iz tkiva posteljice kod uvjeta trodimenzionalnog kultiviranja.
2. Postupak prema zahtjevu 1,
a) pri čemu sustav trodimenzionalnog kultiviranja sadrži trodimenzionalni bioreaktor; i/ili
b) pri čemu se adherentne stanice kultiviraju do najmanje 60% konfluencije; i/ili
c) dodatno sadrži izoliranje navedenih adherentnih stanica korištenjem probavnog enzima kao što je kolagenaza; i/ili
d) pri čemu navedeni uvjeti trodimenzionalnog kultiviranja sadrže bioreaktor odabran iz skupine koju čine bioreaktor s klipnim strujanjem, bioreaktor sa neprekidno miješanim spremnikom i bioreaktor sa stacionarnim slojem; i/ili
e) pri čemu se navedena populacija adherentnih stromalnih stanica dobiva od dijelova posteljice odabranih iz skupine koju čine amnion, decidua basalis i decidua parietalis.
3. Izolirana populacija stanica koja sadrži adherentne stromalne stanice tkiva posteljice uzgojene u trodimenzionalnoj kulturi, naznačena time da navedene adherentne stanice
a) luče višu razinu najmanje jednog faktora odabranog iz skupine koju čine SCF, IL-6, i Flt-3 od razine koja je izlučena s adherentnim stanicama iz tkiva posteljice uzgojenog u 2D kulturi; i/ili
b) izražavaju višu razinu najmanje jednog proteina odabranog iz skupine koju čine obitelj histona H2A (H2AF), aldehidna dehidrogenaza X (ALDH X), faktor eukariotske elongacije translacije 2 (EEEF2), retikulokalbin 3, EF-hand kalcijeva vezujuća domena (RCN2) i kalponin 1 osnovnog glatkog mišića (CNN1) u odnosu na razinu koja je izražena s adherentnim stanicama iz tkiva posteljice uzgojenog u 2D kulturi; i/ili
c) izražavaju nižu razinu najmanje jednog proteina odabranog iz skupine koju čine heterogeni stanični ribonukleoprotein H1 (Hnrph1), prekursor CD44 antigen izoforme 2, izoforme 3 fosfoadenozin 5 fosfosulfat sintaze 2 (Papss2) i ribosomni protein L7a (rpL7a) u odnosu na razinu koja je izražena s adherentnim stanicama iz tkiva posteljice uzgojenog u 2D kulturi; i/ili
d) se generiraju prema postupku iz patentnih zahtjeva 1 ili 2.
4. Populacija prema zahtjevu 3, naznačena time da stanice suzbijaju imunološku reakciju.
5. Populacija prema zahtjevu 4, naznačena time da navedeno suzbijanje sadrži smanjenje proliferacije T stanica.
6. Farmaceutski pripravak naznačen time da sadrži populaciju prema bilo kojem od zahtjeva 3-5, te farmaceutski prihvatljiv nosač.
7. Populacija prema bilo kojem od zahtjeva 3-5 ili pripravak prema zahtjevu 6 naznačeni time da su za uporabu za terapiju.
8. Populacija prema bilo kojem od zahtjeva 3-5 ili pripravak prema zahtjevu 6 naznačeni time da su za uporabu za liječenje gubitka krvi, anemije, autoimunih poremećaja, dijabetes melitusa ovisnog o inzulinu, artritisa, multiple skleroze, bolest transplantata protiv domaćina (GvHD), autoimuni encefalomijelitis (EAE), sistemski eritemski lupus (SLE), reumatoidni artritis, sistemska skleroza, Sjogrenov sindrom, mijastenija gravis (MG), Guillain-Barreovog sindroma (GBS), Hashimotovog tiroiditisa (HT), Gravesove bolesti, ili upalne bolesti crijeva.
9. Populacija ili pripravak za uporabu prema zahtjevima 7 ili 8,
a) koja dodatno sadrži davanje matičnih stanica subjektu; proizvoljno pri čemu navedene matične stanice sadržavaju hematopoetske matične stanice; i/ili
b) pri čemu adherentne stanice izražavaju jedan ili više od CD73, CD90, CD29, ili CD105; i/ili
c) pri čemu adherentne stanice ne izražavaju CD45, CD80, HLA-DR, CD11b, CD14, CD19, CD34, ili CD79.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78476906P | 2006-03-23 | 2006-03-23 | |
US84708806P | 2006-09-26 | 2006-09-26 | |
EP12189046.1A EP2548951B1 (en) | 2006-03-23 | 2007-03-22 | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160538T1 true HRP20160538T1 (hr) | 2016-07-15 |
Family
ID=38522837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160538TT HRP20160538T1 (hr) | 2006-03-23 | 2016-05-19 | Postupci za ekspanziju stanice i uporaba tako proizvedenih stanica i obrađenog medija za terapiju |
Country Status (21)
Country | Link |
---|---|
US (2) | US20110129447A1 (hr) |
EP (5) | EP2548951B1 (hr) |
JP (3) | JP5733894B2 (hr) |
KR (2) | KR101557256B1 (hr) |
CN (1) | CN105296415A (hr) |
AU (1) | AU2007228341B2 (hr) |
BR (1) | BRPI0709349A2 (hr) |
CA (1) | CA2646384C (hr) |
DK (2) | DK2626417T3 (hr) |
ES (3) | ES2549528T3 (hr) |
HK (5) | HK1136846A1 (hr) |
HR (1) | HRP20160538T1 (hr) |
HU (1) | HUE028796T2 (hr) |
IL (1) | IL236213A (hr) |
MX (1) | MX2008012085A (hr) |
PL (2) | PL2366775T3 (hr) |
PT (3) | PT2366775E (hr) |
RU (1) | RU2433177C2 (hr) |
SG (1) | SG170761A1 (hr) |
SI (1) | SI2548951T1 (hr) |
WO (1) | WO2007108003A2 (hr) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
EP1641914B1 (en) | 2003-06-27 | 2016-07-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
PL1971681T3 (pl) | 2005-12-16 | 2018-01-31 | Depuy Synthes Products Inc | Kompozycje oraz sposoby do hamowania niepożądanej odpowiedzi immunologicznej w przypadku transplantacji z brakiem zgodności tkankowej |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
SG170761A1 (en) * | 2006-03-23 | 2011-05-30 | Pluristem Ltd | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
WO2008060541A2 (en) * | 2006-11-13 | 2008-05-22 | Ethicon, Incorporated | In vitro expansion of postpartum-derived cells using microcarriers |
NZ578819A (en) * | 2007-02-12 | 2012-02-24 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
JP5162784B2 (ja) * | 2007-07-11 | 2013-03-13 | 日東電工株式会社 | 細胞培養基材及びその製造方法並びに細胞培養方法 |
AU2013267050B2 (en) * | 2007-09-19 | 2016-01-07 | Pluristem Ltd. | Adherent cells from adipose or placenta tissues and use thereof in therapy |
CN107050057B (zh) | 2007-09-19 | 2021-04-20 | 普拉里斯坦有限公司 | 来自脂肪或胎盘组织的粘附细胞及其在治疗中的用途 |
EP2303293A1 (en) | 2008-05-27 | 2011-04-06 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
DK2330889T3 (en) | 2008-08-20 | 2017-01-30 | Anthrogenesis Corp | Improved cell composition and process for making the same |
MX2011002328A (es) * | 2008-09-02 | 2011-05-19 | Pluristem Ltd | Celulas adherentes del tejido de placenta y su uso en terapia. |
EP2331957B1 (en) * | 2008-09-02 | 2016-11-02 | Pluristem Ltd. | Methods of selection of cells for transplantation |
EP2334310B1 (en) * | 2008-09-02 | 2016-06-29 | Pluristem Ltd. | Adherent cells from placenta tissue and use thereof in therapy |
AU2009327384B2 (en) | 2008-12-19 | 2014-07-10 | DePuy Synthes Products, LLC | Treatment of lung and pulmonary diseases and disorders |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
CN102498204B (zh) | 2009-03-26 | 2015-02-04 | 德普伊新特斯产品有限责任公司 | 人脐带组织细胞作为用于阿尔茨海默病的疗法 |
IL288647B2 (en) * | 2009-11-30 | 2023-12-01 | Pluri Biotech Ltd | Adherent cells of placental origin and their use for the treatment of heart failure |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9757419B2 (en) | 2010-05-27 | 2017-09-12 | Pluristem Ltd. | Skeletal muscle regeneration using mesenchymal system cells |
CN103180435A (zh) * | 2010-08-31 | 2013-06-26 | 库克通用生物技术有限责任公司 | 用于治疗动物疾病的全身的同种异体干细胞疗法 |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
CN103501796A (zh) | 2011-03-04 | 2014-01-08 | 艾哈迈德·H·阿勒卡塔尼 | 护肤霜 |
KR101835917B1 (ko) * | 2011-03-22 | 2018-03-07 | 플루리스템 리미티드 | 방사선 또는 화학적 손상을 치료하는 방법들 |
ES2768296T3 (es) * | 2011-04-15 | 2020-06-22 | Pluristem Ltd | Métodos y sistemas para recoger células |
ITTO20111183A1 (it) * | 2011-12-21 | 2013-06-22 | Univ Degli Studi Torino | Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia |
AU2013311289B2 (en) | 2012-09-04 | 2017-11-16 | Pluristem Ltd. | Methods for prevention and treatment of preeclampsia |
DK2739720T3 (en) | 2012-09-06 | 2015-03-02 | Pluristem Ltd | Devices and methods for growing cells |
US10351910B2 (en) | 2013-02-20 | 2019-07-16 | Pluristem Ltd | Gene and protein expression properties of adherent stromal cells cultured in 3D |
WO2014141111A1 (en) | 2013-03-14 | 2014-09-18 | Pluristem Ltd. | Methods for prevention and treatment of graft-versus-host disease |
RU2525143C1 (ru) * | 2013-03-22 | 2014-08-10 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук | СПОСОБ ЭКСПАНСИИ МОНОНУКЛЕАРНЫХ КЛЕТОК ПУПОВИННОЙ КРОВИ (пкМНК) ex vivo В ПРИСУТСТВИИ МУЛЬТИПОТЕНТНЫХ СТРОМАЛЬНЫХ МЕЗЕНХИМАЛЬНЫХ КЛЕТОК (ММСК) |
RU2539750C2 (ru) * | 2013-04-09 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ оценки иммуносупрессивных свойств мезенхимальных стромальных клеток человека |
WO2015004609A2 (en) | 2013-07-09 | 2015-01-15 | Pluristem Ltd. | Adherent cells from placenta and use thereof in treatment of injured tendons |
EP3027235A1 (en) | 2013-07-30 | 2016-06-08 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
WO2015025059A1 (en) * | 2013-08-23 | 2015-02-26 | Fundacion Pública Andaluza Progreso Y Salud | Cd105-negative multipotent mesenchymal stromal cells |
JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
WO2015132729A1 (en) | 2014-03-04 | 2015-09-11 | Pluristem Ltd. | Systems and methods for growing and harvesting cells |
JP6783143B2 (ja) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | 培地の受動的補充 |
CN106715676A (zh) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | 按计划供养 |
RU2644650C2 (ru) | 2014-12-01 | 2018-02-13 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток и способ его получения |
US10258652B2 (en) | 2014-12-18 | 2019-04-16 | Pluristem Ltd. | Methods and compositions for treating and preventing muscle wasting disorders |
WO2016151476A1 (en) | 2015-03-23 | 2016-09-29 | Pluristem Ltd. | Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
RU2628092C1 (ru) * | 2016-02-10 | 2017-08-14 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) | Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+ |
CN109072189A (zh) * | 2016-02-12 | 2018-12-21 | 细胞治疗药物公司 | 脂肪组织衍生的间充质基质细胞条件培养基及其制备和使用方法 |
WO2017141181A1 (en) | 2016-02-18 | 2017-08-24 | Pluristem Ltd. | Methods and compositions for treating cancers and neoplasms |
RU2708329C2 (ru) | 2016-05-31 | 2019-12-05 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток, композиции и способы применения |
CN109496236A (zh) | 2016-06-06 | 2019-03-19 | 普拉里斯坦有限公司 | 改变的粘附基质细胞及其产生和使用方法 |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
WO2018150381A1 (en) * | 2017-02-20 | 2018-08-23 | Pluristem Ltd. | Methods and compositions for tumor assessment |
WO2018183998A1 (en) * | 2017-03-31 | 2018-10-04 | Cellum Biomedical, Inc. | Biocompatible conditioned cell medium compositions and uses thereof |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656841A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
US20200246386A1 (en) | 2017-04-24 | 2020-08-06 | Pluristem Ltd. | Methods and compositions for treating neurological disorders |
CN110662833A (zh) * | 2017-04-25 | 2020-01-07 | 北海道公立大学法人札幌医科大学 | 间充质干细胞的制造方法、间充质干细胞的治疗效果标志物和治疗效果判断方法、以及包含间充质干细胞的细胞制剂 |
IL260253A (en) | 2017-07-03 | 2019-01-31 | Pluristem Ltd | Methods and compounds for removing adherent cells |
EP3720948A1 (en) | 2018-03-12 | 2020-10-14 | Universidade do Porto | Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells |
US20240082313A1 (en) * | 2021-01-26 | 2024-03-14 | The Trustees Of Indiana University | Pharmaceutical compositions and their methods of use |
CN112813002B (zh) * | 2021-02-07 | 2022-11-08 | 天津科技大学 | 一株耐热短乳杆菌及其后生素制剂的应用 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5266476A (en) | 1985-06-18 | 1993-11-30 | Yeda Research & Development Co., Ltd. | Fibrous matrix for in vitro cell cultivation |
US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US6326198B1 (en) | 1990-06-14 | 2001-12-04 | Regents Of The University Of Michigan | Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US6010696A (en) | 1990-11-16 | 2000-01-04 | Osiris Therapeutics, Inc. | Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5168085A (en) | 1991-05-20 | 1992-12-01 | Corning Incorporated | Multi-stage twc system |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5629186A (en) | 1994-04-28 | 1997-05-13 | Lockheed Martin Corporation | Porous matrix and method of its production |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5925567A (en) | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
US6132463A (en) | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
PT868505E (pt) | 1995-11-16 | 2005-06-30 | Univ Case Western Reserve | Inducao condrogenica in vitro de celulas estaminais mesenquimais humanas |
US6087129A (en) * | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
US6291240B1 (en) * | 1998-01-29 | 2001-09-18 | Advanced Tissue Sciences, Inc. | Cells or tissues with increased protein factors and methods of making and using same |
EP1064353B1 (en) | 1998-03-18 | 2002-11-06 | Massachusetts Institute Of Technology | Vascularized perfused microtissue/micro-organ arrays |
EP1108011A2 (en) | 1998-06-08 | 2001-06-20 | Osiris Therapeutics, Inc. | In vitro maintenance of hematopoietic stem cells |
US6153432A (en) | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
MXPA01007820A (es) * | 1999-02-04 | 2003-06-19 | Technion Res & Dev Foundation | Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras. |
JP2002537849A (ja) * | 1999-03-10 | 2002-11-12 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 脂肪由来の幹細胞および格子 |
WO2000073421A2 (en) | 1999-06-02 | 2000-12-07 | Lifebank Services, L.L.C. | Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells |
US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
DK1261694T3 (da) | 2000-02-26 | 2008-05-26 | Artecel Inc | Pluripotente stamceller som er genereret ud fra stromaceller der er afledt af adipöst væv samt anvendelser deraf |
US6905875B2 (en) * | 2000-10-12 | 2005-06-14 | National University Of Singapore | Non-disruptive three-dimensional culture and harvest system for anchorage-dependent cells |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
DK1349918T3 (da) * | 2000-12-06 | 2014-11-10 | Anthrogenesis Corp | Fremgangsmåde til indsamling af stamceller fra moderkagen |
KR100973615B1 (ko) * | 2001-02-14 | 2010-08-02 | 안트로제네시스 코포레이션 | 산후 포유류의 태반, 이의 용도 및 태반 줄기세포 |
EP2336299A1 (en) * | 2001-02-14 | 2011-06-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
MXPA04004310A (es) * | 2001-11-09 | 2005-03-31 | Artecel Sciences Inc | Metodos y composiciones para el uso de celulas estromales para soportar celulas madre embrionarias y adultas. |
JP2003180334A (ja) * | 2001-12-17 | 2003-07-02 | Japan Science & Technology Corp | 三次元高密度細胞培養用モジュール |
US7504099B2 (en) | 2001-12-27 | 2009-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of inducing or enhancing connective tissue repair |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1497435A4 (en) * | 2002-04-19 | 2005-07-27 | Univ Pittsburgh | PLACENTAL STEM CELLS AND USES |
US20060172304A1 (en) | 2003-02-27 | 2006-08-03 | Elaine Fuchs | Method for modulating epithelial stem cell lineage |
EP1641914B1 (en) * | 2003-06-27 | 2016-07-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US6924458B2 (en) | 2003-07-17 | 2005-08-02 | Great Computer Corp. | Auxiliary focusing tool for laser marker |
EP1756267A2 (en) * | 2004-05-14 | 2007-02-28 | Becton, Dickinson and Company | Stem cell populations and methods of use |
DE102004043256B4 (de) * | 2004-09-07 | 2013-09-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension |
CA2602684C (en) | 2005-03-31 | 2014-07-22 | Stemnion, Inc. | Amnion-derived cell compositions, methods of making and uses thereof |
EP1994143A4 (en) * | 2006-02-06 | 2009-08-26 | Pluristem Ltd | METHOD AND DEVICE FOR MAINTAINING AND EXPANSION OF HEMOPOETIC STEM CELLS FROM MONONUCLEAR CELLS |
SG170761A1 (en) * | 2006-03-23 | 2011-05-30 | Pluristem Ltd | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
KR101835917B1 (ko) * | 2011-03-22 | 2018-03-07 | 플루리스템 리미티드 | 방사선 또는 화학적 손상을 치료하는 방법들 |
-
2007
- 2007-03-22 SG SG201102089-8A patent/SG170761A1/en unknown
- 2007-03-22 CN CN201510738761.1A patent/CN105296415A/zh active Pending
- 2007-03-22 WO PCT/IL2007/000380 patent/WO2007108003A2/en active Application Filing
- 2007-03-22 EP EP12189046.1A patent/EP2548951B1/en active Active
- 2007-03-22 PL PL11170055T patent/PL2366775T3/pl unknown
- 2007-03-22 MX MX2008012085A patent/MX2008012085A/es active IP Right Grant
- 2007-03-22 JP JP2009502327A patent/JP5733894B2/ja active Active
- 2007-03-22 ES ES13164303.3T patent/ES2549528T3/es active Active
- 2007-03-22 ES ES12189046T patent/ES2572214T3/es active Active
- 2007-03-22 EP EP16157193.0A patent/EP3091071B1/en active Active
- 2007-03-22 RU RU2008141894/10A patent/RU2433177C2/ru active
- 2007-03-22 DK DK13164303.3T patent/DK2626417T3/en active
- 2007-03-22 CA CA2646384A patent/CA2646384C/en active Active
- 2007-03-22 EP EP07713395A patent/EP2010647A4/en not_active Withdrawn
- 2007-03-22 KR KR1020147029038A patent/KR101557256B1/ko active IP Right Grant
- 2007-03-22 AU AU2007228341A patent/AU2007228341B2/en active Active
- 2007-03-22 SI SI200731782A patent/SI2548951T1/sl unknown
- 2007-03-22 PT PT111700555T patent/PT2366775E/pt unknown
- 2007-03-22 KR KR1020087025460A patent/KR101490449B1/ko active IP Right Grant
- 2007-03-22 BR BRPI0709349-7A patent/BRPI0709349A2/pt not_active Application Discontinuation
- 2007-03-22 ES ES11170055.5T patent/ES2537641T3/es active Active
- 2007-03-22 PT PT121890461T patent/PT2548951E/pt unknown
- 2007-03-22 PL PL12189046T patent/PL2548951T3/pl unknown
- 2007-03-22 DK DK11170055.5T patent/DK2366775T3/en active
- 2007-03-22 EP EP13164303.3A patent/EP2626417B1/en active Active
- 2007-03-22 EP EP20110170055 patent/EP2366775B1/en active Active
- 2007-03-22 US US12/225,478 patent/US20110129447A1/en not_active Abandoned
- 2007-03-22 PT PT131643033T patent/PT2626417E/pt unknown
- 2007-03-22 HU HUE12189046A patent/HUE028796T2/en unknown
-
2010
- 2010-04-08 HK HK10103472.9A patent/HK1136846A1/xx not_active IP Right Cessation
-
2011
- 2011-06-16 JP JP2011133774A patent/JP5766041B2/ja active Active
-
2012
- 2012-01-17 HK HK13104666.0A patent/HK1177759A1/zh unknown
- 2012-01-17 HK HK14100827.3A patent/HK1187950A1/xx unknown
- 2012-01-17 HK HK12100543.8A patent/HK1160174A1/xx not_active IP Right Cessation
-
2013
- 2013-12-20 JP JP2013263148A patent/JP5941454B2/ja active Active
-
2014
- 2014-12-11 IL IL236213A patent/IL236213A/en active IP Right Grant
-
2015
- 2015-10-01 US US14/873,092 patent/US20160022738A1/en not_active Abandoned
-
2016
- 2016-05-12 HK HK16105449.8A patent/HK1217513A1/zh unknown
- 2016-05-19 HR HRP20160538TT patent/HRP20160538T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160538T1 (hr) | Postupci za ekspanziju stanice i uporaba tako proizvedenih stanica i obrađenog medija za terapiju | |
JP2009531059A5 (hr) | ||
Oberbauer et al. | Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art | |
Shaw et al. | Clinical applications of prenatal and postnatal therapy using stem cells retrieved from amniotic fluid | |
Liang et al. | Interferon-γ mediates the immunosuppression of bone marrow mesenchymal stem cells on T-lymphocytes in vitro | |
Cras et al. | Update on mesenchymal stem cell-based therapy in lupus and scleroderma | |
Ciuffi et al. | Adipose stem cells for bone tissue repair | |
Wang et al. | CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells | |
Rebelatto et al. | Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue | |
Tong et al. | Generation of mesenchymal stem cell from human umbilical cord tissue using a combination enzymatic and mechanical disassociation method | |
Liu et al. | Mesenchymal stem cells ameliorate Th1-induced pre-eclampsia-like symptoms in mice via the suppression of TNF-α expression | |
CN102639692B (zh) | 来源于胎盘的贴壁细胞及其在疾病治疗中的应用 | |
JP2011529706A5 (hr) | ||
MX2019007708A (es) | Nuevos agentes anti-inflamatorios. | |
Jia et al. | Isolation and characterization of human mesenchymal stem cells derived from synovial fluid by magnetic‐activated cell sorting (MACS) | |
WO2007015906A3 (en) | Methods and compositions for smooth muscle reconstruction | |
Chae et al. | Immunomodulatory effects of soluble factors secreted by feline adipose tissue-derived mesenchymal stem cells | |
Wang et al. | The chondrogenic potential of progenitor cells derived from peripheral blood: a systematic review | |
Podestà et al. | Mesenchymal stromal cell therapy in solid organ transplantation | |
Al-Jezani et al. | Isolation and characterization of an adult stem cell population from human epidural fat | |
Kim et al. | Paradoxical effects of human adipose tissue-derived mesenchymal stem cells on progression of experimental arthritis in SKG mice | |
Li et al. | TNFAIP6 defines the MSC subpopulation with enhanced immune suppression activities | |
Li et al. | The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy | |
Sun et al. | Human umbilical cord blood-derived stromal cells are superior to human umbilical cord blood-derived mesenchymal stem cells in inducing myeloid lineage differentiation in vitro | |
Reddy et al. | Mesenchymal stem cells as immunomodulator therapies for immune-mediated systemic dermatoses |